• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of procbhomepageaboutsubmitalertseditorial board
Proc Biol Sci. Sep 22, 1997; 264(1386): 1287–1291.
PMCID: PMC1688596

Adaptation to the fitness costs of antibiotic resistance in Escherichia coli.

Abstract

Policies aimed at alleviating the growing problem of drug-resistant pathogens by restricting antimicrobial usage implicitly assume that resistance reduces the Darwinian fitness of pathogens in the absence of drugs. While fitness costs have been demonstrated for bacteria and viruses resistant to some chemotherapeutic agents, these costs are anticipated to decline during subsequent evolution. This has recently been observed in pathogens as diverse as HIV and Escherichia coli. Here we present evidence that these gentic adaptations to the costs of resistance can virtually preclude resistant lineages from reverting to sensitivity. We show that second site mutations which compensate for the substantial (14 and 18% per generation) fitness costs of streptomycin resistant (rpsL) mutations in E. coli create a genetic background in which streptomycin sensitive, rpsL+ alleles have a 4-30% per generation selective disadvantage relative to adapted, resistant strains. We also present evidence that similar compensatory mutations have been fixed in long-term streptomycin-resistant laboratory strains of E. coli and may account for the persistence of rpsL streptomycin resistance in populations maintained for more than 10,000 generations in the absence of the antibiotic. We discuss the public health implications of these and other experimental results that question whether the more prudent use of antimicrobial chemotherapy will lead to declines in the incidence of drug-resistant pathogenic microbes.

Full Text

The Full Text of this article is available as a PDF (108K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Bloch CA, Rode CK. Pathogenicity island evaluation in Escherichia coli K1 by crossing with laboratory strain K-12. Infect Immun. 1996 Aug;64(8):3218–3223. [PMC free article] [PubMed]
  • Borman AM, Paulous S, Clavel F. Resistance of human immunodeficiency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug. J Gen Virol. 1996 Mar;77(Pt 3):419–426. [PubMed]
  • Boucher CA, van Leeuwen R, Kellam P, Schipper P, Tijnagel J, Lange JM, Larder BA. Effects of discontinuation of zidovudine treatment on zidovudine sensitivity of human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother. 1993 Jul;37(7):1525–1530. [PMC free article] [PubMed]
  • Bouma JE, Lenski RE. Evolution of a bacteria/plasmid association. Nature. 1988 Sep 22;335(6188):351–352. [PubMed]
  • Conlon CP, Klenerman P, Edwards A, Larder BA, Phillips RE. Heterosexual transmission of human immunodeficiency virus type 1 variants associated with zidovudine resistance. J Infect Dis. 1994 Feb;169(2):411–415. [PubMed]
  • Elena SF, Cooper VS, Lenski RE. Punctuated evolution caused by selection of rare beneficial mutations. Science. 1996 Jun 21;272(5269):1802–1804. [PubMed]
  • Kellam P, Boucher CA, Tijnagel JM, Larder BA. Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance. J Gen Virol. 1994 Feb;75(Pt 2):341–351. [PubMed]
  • Larder BA, Kemp SD. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science. 1989 Dec 1;246(4934):1155–1158. [PubMed]
  • Lederberg S. Genetics of host-controlled restriction and modification of deoxyribonucleic acid in Escherichia coli. J Bacteriol. 1966 Mar;91(3):1029–1036. [PMC free article] [PubMed]
  • Lenski RE. Quantifying fitness and gene stability in microorganisms. Biotechnology. 1991;15:173–192. [PubMed]
  • Lenski RE, Simpson SC, Nguyen TT. Genetic analysis of a plasmid-encoded, host genotype-specific enhancement of bacterial fitness. J Bacteriol. 1994 Jun;176(11):3140–3147. [PMC free article] [PubMed]
  • Lenski RE, Travisano M. Dynamics of adaptation and diversification: a 10,000-generation experiment with bacterial populations. Proc Natl Acad Sci U S A. 1994 Jul 19;91(15):6808–6814. [PMC free article] [PubMed]
  • Levin BR, Lipsitch M, Perrot V, Schrag S, Antia R, Simonsen L, Walker NM, Stewart FM. The population genetics of antibiotic resistance. Clin Infect Dis. 1997 Jan;24 (Suppl 1):S9–16. [PubMed]
  • Levy SB. Balancing the drug-resistance equation. Trends Microbiol. 1994 Oct;2(10):341–342. [PubMed]
  • Schrag SJ, Perrot V. Reducing antibiotic resistance. Nature. 1996 May 9;381(6578):120–121. [PubMed]
  • Singer M, Baker TA, Schnitzler G, Deischel SM, Goel M, Dove W, Jaacks KJ, Grossman AD, Erickson JW, Gross CA. A collection of strains containing genetically linked alternating antibiotic resistance elements for genetic mapping of Escherichia coli. Microbiol Rev. 1989 Mar;53(1):1–24. [PMC free article] [PubMed]
  • Travisano M, Lenski RE. Long-term experimental evolution in Escherichia coli. IV. Targets of selection and the specificity of adaptation. Genetics. 1996 May;143(1):15–26. [PMC free article] [PubMed]
  • Travisano M, Mongold JA, Bennett AF, Lenski RE. Experimental tests of the roles of adaptation, chance, and history in evolution. Science. 1995 Jan 6;267(5194):87–90. [PubMed]

Articles from Proceedings of the Royal Society B: Biological Sciences are provided here courtesy of The Royal Society

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links